SpaceX prices stock at $135, setting valuation near $1.8 trillion
SpaceX priced shares at $135 in SEC filing, implying a valuation near $1.8 trillion before Friday's Nasdaq debut.
1 min read
Adam Schwartz
Adam Schwartz is a staff writer at P&L, covering markets, economic policy, and the financial system. He previously worked in credit research, analyzing corporate debt, rate cycles, and balance-sheet risk.
World Bank cuts global growth forecast to 2.5% for 2026
The World Bank cut its 2026 global growth forecast to 2.5%, the weakest outlook since the pandemic began in 2019.
1 min read
SpaceX plans public share sale at $1.75 trillion valuation
Bankers value SpaceX at $1.75 trillion in the planned share sale, putting it among the world’s 10 most valuable companies.
1 min read
U.S. consumer prices rise 4.2% in May as Iran conflict lifts energy costs
U.S. consumer prices rose at a 4.2% annual rate in May, the fastest pace in three years, as Iran-related energy disruptions lifted costs.
2 min read
NY Fed survey shows 43.7% of households feel worse off than a year ago
43.7% of households said they were worse off financially than a year ago in the New York Fed survey.
1 min read
Factories, Restaurants and City Halls Add Workers as Hiring Widens
Employers added more than half a million jobs from March through May, a sharp shift from last year’s slowdown.
1 min read
Consumers see weaker finances and job prospects in NY Fed May survey
The share of households saying they are worse off financially rose to 43.7%, the highest since January 2023.
3 min read
TSMC Grows Gross Margin to 59.9% as Fabless Chip Designers Rely on Its Nodes
TSMC leverages its neutral foundry model to turn product design risks into a manufacturing annuity, yielding a 59.9% gross margin in 2025.
5 min read
Federal drug pricing policies force GLP-1 margin compression and volume dependency
Federal price caps limiting GLP-1 treatments to $350 monthly force pharmaceutical companies to trade premium margins for mass-market volume.
5 min read
GLP-1 mass market demand collides with specialty drug pricing
The transition of obesity into a pharmacologically treated chronic condition forces an immediate collision between mass-market demand and specialty-drug pricing.
7 min read
Novo Nordisk and Eli Lilly manufacturing bottlenecks constrain the GLP-1 market
Novo Nordisk and Eli Lilly control the GLP-1 market through a physical ceiling on sterile fill-finish capacity, forcing competitors out and driving billions into vertical integration.
8 min read
High obesity drug costs force payers to reallocate capital from traditional healthcare services
Physical limits in peptide synthesis and sterile fill-finish operations place a hard ceiling on near-term revenue growth for the prevailing pharmaceutical duopoly.
7 min read